<DOC>
	<DOCNO>NCT00640601</DOCNO>
	<brief_summary>A Multicentre , Open-label , Prospective Long-term Study Evaluating Clinical Benefit Effectiveness SEROQUEL XRÂ® ( Quetiapine Fumarate Extended-Release Tablets ) Subjects Schizophrenia .</brief_summary>
	<brief_title>Study Evaluating Clinical Benefit SEROQUEL XR Subjects With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Provision write informed consent initiation study related procedure . Male female subject age 18 65 year , inclusive . Documented clinical diagnosis meeting Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSMIV ) criterion follow : Schizophrenia DSMIV , catatonic 295.20 , disorganise 295.10 , paranoid 295.30 undifferentiated 295.90 . Outpatient status . Subjects and/or Principal Investigator 's opinion , consider ongoing antipsychotic treatment inadequate insufficient efficacy , poor tolerance , and/or non acceptability actual dosage regimen ( eg . b.i.d , t.i.d , etc ) . Monotherapy current antipsychotic least 7 day prior initiate treatment ( ie , one antipsychotic 7 day period prior initiate study medication ) . Note : Subjects b.i.d regimen seroquel IR 7 day prior enrolment eligible participate study . Female subject childbearing potential must negative serum pregnancy test enrolment willing use reliable method birth control , ie , barrier method , oral contraceptive , implant , dermal contraception , longterm injectable contraceptive , intrauterine device , tubal ligation study . Capable make treatment decision , include able understand comply requirement study , judge Principal Investigator . Be able read write either English French grade 7 proficiency level . First episode , drug naive schizophrenic subject . Meeting criterion ( schizophrenia ) DSMIV Axis I diagnosis , concomitant organic mental disorder mental retardation opinion Principal Investigator may interfere study conduct interpretation . Substance/alcohol dependence abuse enrolment [ except dependence full remission ( &gt; 3 month ) except caffeine nicotine dependence ] define DSMIV criterion . A urine drug screen perform . The Principal Investigator evaluate result along medical history determine patient meet DSMIV criterion substance abuse dependence . However , single urine toxicology screen cocaine , heroin , methamphetamine PCP lead exclusion . Subjects require treatment another antipsychotic agent investigational product study . Subjects seroquel IR daily . Known lack response clozapine treatment clozapine within 4 week prior enrolment . Known intolerance seroquel IR . Subjects require treatment disallow medication follow enrolment study . Subjects require treatment epilepsy . Subjects pose imminent risk suicide danger others , judge Principal Investigator . Pregnancy lactation . A thyroidstimulating hormone ( TSH ) concentration 10 % upper limit normal range laboratory use sample analysis whether patient treat hypothyroidism hyperthyroidism . Use depot longacting injectable antipsychotic drug within 1 dose interval Day 1 treatment treatment . Use drug induce inhibit hepatic metabolising cytochrome P450 3A4 enzyme within 14 day screen assessment period ( Day 7 0 ) . See Table 5 . History idiopathic druginduced agranulocytosis . A QTc interval longer 450 msec ( calculate use Fridericia correction heart rate ) ECG consider show cardiac abnormality enrolment determine centrally locate , experienced cardiologist , confirm Principal Investigator clinically significant . Evidence clinically relevant disease ( eg , renal , hepatic , autonomic , endocrine , hematologic ophthalmologic impairment , significant coronary artery disease , congestive heart failure , cerebrovascular disease , viral hepatitis B C , acquire immunodeficiency syndrome [ AIDS ] cancer ) clinical find unstable , opinion Principal Investigator , would negatively affected investigational product would affect investigational product . Laboratory test result outside reference range consider Principal Investigator clinically significant potentially interfere study outcome . A patient Diabetes Mellitus ( DM ) fulfil one follow criterion : Unstable DM define HbA1c &gt; 8.5 % enrolment . Admitted hospital treatment DM DM relate illness past 12 week . Not care physician responsible patient 's DM care . Physician responsible patient 's DM care indicate patient 's DM control . Physician responsible patient 's DM care approve patient 's participation study . Has dose oral hypoglycemic drug ( ) and/or diet four ( 4 ) week prior randomisation . For thiazolidinediones ( glitazones ) period le 8 week . Taking insulin whose daily dose one occasion past 4 week 10 % mean dose precede 4 week . Note : If diabetic patient meet one criterion patient exclude even treat physician believe patient stable participate study . An absolute neutrophil count ( ANC ) &lt; 1.5 x 109/L Inability accommodate visit schedule . History noncompliance judge Principal Investigator . Previous enrolment present study . Participation another clinical study compassionate use programme within 4 week screen ( Day 7 0 ) . Involvement plan conduct study ( applies AstraZeneca staff staff study site ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Seroquel</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>Extended Release</keyword>
</DOC>